Atossa Therapeutics Dirección
Dirección controles de criterios 3/4
El CEO de Atossa Therapeutics' es Steve Quay , nombrado en Apr 2009, tiene una permanencia de 15.08 años. compensación anual total es $2.36M, compuesta por 30% salario y 70% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.002% de las acciones de la empresa, por valor de $4.01K. La antigüedad media del equipo directivo y de la junta directiva es de 3.3 años y 12.3 años, respectivamente.
Información clave
Steve Quay
Chief Executive Officer (CEO)
US$2.4m
Compensación total
| Porcentaje del salario del CEO | 30.0% |
| Permanencia del CEO | 15.1yrs |
| Participación del CEO | 0.002% |
| Permanencia media de la dirección | 3.3yrs |
| Promedio de permanencia en la Junta Directiva | 10.2yrs |
Actualizaciones recientes de la dirección
Recent updates
Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans
Mar 07
We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate
Nov 08Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth
Apr 26We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate
Jan 09Atossa Therapeutics: Still Gets An 'Incomplete' Rating
Oct 11We're Hopeful That Atossa Therapeutics (NASDAQ:ATOS) Will Use Its Cash Wisely
Sep 25Atossa Therapeutics GAAP EPS of -$0.05
Aug 08Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth
May 12A First Assessment On Atossa Therapeutics
Dec 10We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate
Dec 02Atossa Therapeutics: Diversification Into COVID Makes Sense In A Variants World
Sep 22Atossa Therapeutics (NASDAQ:ATOS) Is In A Strong Position To Grow Its Business
Jul 17Atossa Therapeutics: Hope Springs Eternal
Jun 30Atossa Therapeutics to be included in the Russell 2000, 3000 indexes
Jun 16Atossa reaches a two-year high ahead of data readout for breast cancer therapy
Jun 07Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans
Apr 02Atossa updates on single-patient study for Endoxifen
Feb 04Atossa halts Endoxifen breast cancer study after positive data
Feb 02Atossa Therapeutics prices ~$25M direct offering, stock -23% PM
Jan 06Atossa Therapeutics prices $14M registered direct offering
Dec 17We're A Little Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate
Dec 10
Atossa Therapeutics plummets 38% after it raises $20M in public offering
Dec 09Atossa Therapeutics EPS in-line
Nov 13Safety data on COVID-19 nasal spray fails to lift Atossa, down 6%
Nov 10Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | US$2m | US$706k | -US$30m |
| Sep 30 2023 | n/a | n/a | -US$30m |
| Jun 30 2023 | n/a | n/a | -US$32m |
| Mar 31 2023 | n/a | n/a | -US$28m |
| Dec 31 2022 | US$3m | US$706k | -US$27m |
| Sep 30 2022 | n/a | n/a | -US$24m |
| Jun 30 2022 | n/a | n/a | -US$21m |
| Mar 31 2022 | n/a | n/a | -US$22m |
| Dec 31 2021 | US$6m | US$659k | -US$21m |
| Sep 30 2021 | n/a | n/a | -US$28m |
| Jun 30 2021 | n/a | n/a | -US$26m |
| Mar 31 2021 | n/a | n/a | -US$23m |
| Dec 31 2020 | US$3m | US$601k | -US$22m |
| Sep 30 2020 | n/a | n/a | -US$13m |
| Jun 30 2020 | n/a | n/a | -US$13m |
| Mar 31 2020 | n/a | n/a | -US$16m |
| Dec 31 2019 | US$6m | US$601k | -US$17m |
| Sep 30 2019 | n/a | n/a | -US$17m |
| Jun 30 2019 | n/a | n/a | -US$17m |
| Mar 31 2019 | n/a | n/a | -US$25m |
| Dec 31 2018 | US$2m | US$582k | -US$23m |
| Sep 30 2018 | n/a | n/a | -US$23m |
| Jun 30 2018 | n/a | n/a | -US$22m |
| Mar 31 2018 | n/a | n/a | -US$11m |
| Dec 31 2017 | US$1m | US$520k | -US$11m |
Compensación vs. Mercado: La compensación total de Steve($USD2.36M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD1.60M).
Compensación vs. Ingresos: La compensación de Steve ha sido consistente con los resultados de la empresa en el último año.
CEO
Steve Quay (72 yo)
15.1yrs
Permanencia
US$2,356,220
Compensación
Dr. Steven C. Quay, also known as Steve, M.D., Ph D., FCAP, has been the Chief Executive Officer and President of Atossa Therapeutics, Inc. (formerly known as Atossa Genetics Inc.) since April 30, 2009 and...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman | 15.1yrs | US$2.36m | 0.0021% $ 4.5k | |
| Senior VP of Finance & Principal Accounting Officer | 3.3yrs | US$687.46k | 0% $ 0 | |
| Senior Vice President of Administration & HR | 9.8yrs | sin datos | sin datos | |
| Vice President of Investor & Public Relations | 2.3yrs | sin datos | sin datos | |
| Interim Chief Medical Officer | 1.6yrs | sin datos | sin datos |
3.3yrs
Permanencia media
Equipo directivo experimentado: El equipo directivo de ATOS se considera experimentado (3.3 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman | 15.1yrs | US$2.36m | 0.0021% $ 4.5k | |
| Independent Director | 10.2yrs | US$146.17k | 0% $ 0 | |
| Independent Director | 12.8yrs | US$144.92k | 0.000080% $ 168.4 | |
| Independent Director | less than a year | US$93.98k | 0.020% $ 42.0k | |
| Independent Director | less than a year | sin datos | sin datos |
10.2yrs
Permanencia media
66yo
Promedio de edad
Junta con experiencia: Los miembros de la junta directiva de ATOS son experimentados ( 12.2 años antigüedad media).